Literature DB >> 26760133

Trifluoperazine: A Sprightly Old Drug.

Robert H Howland.   

Abstract

Trifluoperazine, developed in the mid-1950s and introduced in 1959 as an anxiolytic and antipsychotic agent, has been an extensively studied drug molecule that has been used as a calmodulin inhibitor. Regulation of calmodulin has important roles in cellular proliferation, inflammation, neurodegeneration, and other pathological processes. Trifluoperazine also inhibits P-glycoprotein, a protein that transports organic compounds across cell membranes and the blood-brain barrier. Trifluoperazine is currently approved for the treatment of schizophrenia as well as for the treatment of non-psychotic anxiety, but has other potential clinical uses based on calmodulin and P-glycoprotein inhibition. Copyright 2016, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26760133     DOI: 10.3928/02793695-20151223-01

Source DB:  PubMed          Journal:  J Psychosoc Nurs Ment Health Serv        ISSN: 0279-3695            Impact factor:   1.098


  3 in total

1.  Trifluoperazine prolongs the survival of experimental brain metastases by STAT3-dependent lysosomal membrane permeabilization.

Authors:  Xin Zhang; Kaikai Ding; Jianxiong Ji; Himalaya Parajuli; Synnøve Nymark Aasen; Heidi Espedal; Bin Huang; Anjing Chen; Jian Wang; Xingang Li; Frits Thorsen
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

2.  Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination.

Authors:  Xin Zhang; Ran Xu; Chao Zhang; Yangyang Xu; Mingzhi Han; Bin Huang; Anjing Chen; Chen Qiu; Frits Thorsen; Lars Prestegarden; Rolf Bjerkvig; Jian Wang; Xingang Li
Journal:  J Exp Clin Cancer Res       Date:  2017-09-05

3.  Trifluoperazine induces apoptosis through the upregulation of Bax/Bcl‑2 and downregulated phosphorylation of AKT in mesangial cells and improves renal function in lupus nephritis mice.

Authors:  Baodong Wang; Yankun Luo; Xiaoshuang Zhou; Rongshan Li
Journal:  Int J Mol Med       Date:  2018-03-13       Impact factor: 4.101

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.